speb/financial-data huggingface dataset:
GSK balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 14318000000.00
GSK cash_flow (annual, 2022-12-31) — Other Non Cash Items: 350000000.00
GSK balance_sheet (annual, 2022-12-31) — Other Non Current Liabilities: 5779000000.00
GSK balance_sheet (annual, 2022-12-31) — Other Payable: 418000000.00
GSK balance_sheet (annual, 2022-12-31) — Other Properties: 6000000.00
GSK balance_sheet (annual, 2022-12-31) — Other Receivables: 766000000.00
GSK balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 4154000000.00
GSK income_statement (annual, 2022-12-31) — Other Special Charges: -376000000.00
GSK income_statement (annual, 2022-12-31) — Otherunder Preferred Stock Dividend: 0.00
GSK balance_sheet (annual, 2022-12-31) — Payables: 4755000000.00
GSK balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 126000000.00
GSK balance_sheet (annual, 2022-12-31) — Prepaid Assets: 343000000.00
GSK income_statement (annual, 2022-12-31) — Pretax Income: 5628000000.00
GSK balance_sheet (annual, 2022-12-31) — Properties: 0.00
GSK cash_flow (annual, 2022-12-31) — Purchase Of Business: -3374000000.00
GSK cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -1115000000.00
GSK cash_flow (annual, 2022-12-31) — Purchase Of PPE: -1143000000.00
GSK balance_sheet (annual, 2022-12-31) — Raw Materials: 1576000000.00
GSK income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 9554000000.00
GSK income_statement (annual, 2022-12-31) — Reconciled Depreciation: 2147000000.00
GSK income_statement (annual, 2022-12-31) — Rent Expense Supplemental: 17000000.00
GSK cash_flow (annual, 2022-12-31) — Repayment Of Debt: -6668000000.00
GSK income_statement (annual, 2022-12-31) — Research And Development: 5488000000.00
GSK balance_sheet (annual, 2022-12-31) — Restricted Cash: 200000000.00
GSK income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 1607000000.00
GSK balance_sheet (annual, 2022-12-31) — Retained Earnings: 4363000000.00
GSK cash_flow (annual, 2022-12-31) — Sale Of Business: 238000000.00
GSK cash_flow (annual, 2022-12-31) — Sale Of Intangibles: 196000000.00
GSK cash_flow (annual, 2022-12-31) — Sale Of Investment: 1000000.00
GSK cash_flow (annual, 2022-12-31) — Sale Of PPE: 146000000.00
GSK income_statement (annual, 2022-12-31) — Selling General And Administration: 8372000000.00
GSK balance_sheet (annual, 2022-12-31) — Share Issued: 4311343341.00
GSK cash_flow (annual, 2022-12-31) — Short Term Debt Issuance: 1021000000.00
GSK cash_flow (annual, 2022-12-31) — Short Term Debt Payments: 0.00
GSK income_statement (annual, 2022-12-31) — Special Income Charges: -1231000000.00
GSK cash_flow (annual, 2022-12-31) — Stock Based Compensation: 346000000.00
GSK balance_sheet (annual, 2022-12-31) — Stockholders Equity: 10598000000.00
GSK balance_sheet (annual, 2022-12-31) — Tangible Book Value: -10766000000.00
GSK income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: -34398000.00
GSK income_statement (annual, 2022-12-31) — Tax Provision: 707000000.00
GSK income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.13
GSK balance_sheet (annual, 2022-12-31) — Taxes Receivable: 897000000.00
GSK cash_flow (annual, 2022-12-31) — Taxes Refund Paid: -1310000000.00
GSK balance_sheet (annual, 2022-12-31) — Total Assets: 60146000000.00
GSK balance_sheet (annual, 2022-12-31) — Total Capitalization: 26792000000.00
GSK balance_sheet (annual, 2022-12-31) — Total Debt: 20987000000.00
GSK balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 10096000000.00
GSK income_statement (annual, 2022-12-31) — Total Expenses: 22595000000.00
GSK balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 50050000000.00
GSK balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 39377000000.00
GSK balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 27240000000.00
GSK income_statement (annual, 2022-12-31) — Total Operating Income As Reported: 6433000000.00
GSK income_statement (annual, 2022-12-31) — Total Other Finance Cost: 31000000.00
GSK balance_sheet (annual, 2022-12-31) — Total Tax Payable: 471000000.00
GSK income_statement (annual, 2022-12-31) — Total Unusual Items: -273000000.00
GSK income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: -273000000.00
GSK balance_sheet (annual, 2022-12-31) — Tradeand Other Payables Non Current: 932000000.00
GSK balance_sheet (annual, 2022-12-31) — Treasury Shares Number: 217124760.00
GSK balance_sheet (annual, 2022-12-31) — Work In Process: 2286000000.00
GSK balance_sheet (annual, 2022-12-31) — Working Capital: -2041000000.00
GSK income_statement (annual, 2023-12-31) — +Operating Expense: 14418000000.00
GSK income_statement (annual, 2023-12-31) — +Total Revenue: 30328000000.00
GSK balance_sheet (annual, 2023-12-31) — Accounts Payable: 3717000000.00
GSK balance_sheet (annual, 2023-12-31) — Accounts Receivable: 5905000000.00
GSK balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -10259000000.00
GSK balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 3451000000.00
GSK balance_sheet (annual, 2023-12-31) — Allowance For Doubtful Accounts Receivable: -85000000.00
GSK cash_flow (annual, 2023-12-31) — Amortization Cash Flow: 1212000000.00
GSK balance_sheet (annual, 2023-12-31) — Assets Held For Sale Current: 76000000.00
GSK balance_sheet (annual, 2023-12-31) — Available For Sale Securities: 940000000.00
GSK income_statement (annual, 2023-12-31) — Basic Average Shares: 2026000000.00
GSK income_statement (annual, 2023-12-31) — Basic EPS: 2.43
GSK cash_flow (annual, 2023-12-31) — Beginning Cash Position: 3425000000.00
GSK balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 751000000.00
GSK cash_flow (annual, 2023-12-31) — Capital Expenditure: -2344000000.00
GSK balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 1207000000.00
GSK balance_sheet (annual, 2023-12-31) — Capital Stock: 1348000000.00
GSK balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 2746000000.00
GSK balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 4992000000.00
GSK cash_flow (annual, 2023-12-31) — Cash Dividends Paid: -2247000000.00
GSK cash_flow (annual, 2023-12-31) — Change In Inventory: -424000000.00
GSK cash_flow (annual, 2023-12-31) — Change In Other Current Assets: -457000000.00
GSK cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: 492000000.00
GSK cash_flow (annual, 2023-12-31) — Change In Payable: 674000000.00
GSK cash_flow (annual, 2023-12-31) — Change In Receivables: -649000000.00
GSK cash_flow (annual, 2023-12-31) — Change In Working Capital: -364000000.00
GSK cash_flow (annual, 2023-12-31) — Changes In Cash: -468000000.00
GSK balance_sheet (annual, 2023-12-31) — Common Stock: 1348000000.00
GSK cash_flow (annual, 2023-12-31) — Common Stock Dividend Paid: -2247000000.00
GSK balance_sheet (annual, 2023-12-31) — Common Stock Equity: 13347000000.00
GSK cash_flow (annual, 2023-12-31) — Common Stock Issuance: 10000000.00
GSK cash_flow (annual, 2023-12-31) — Common Stock Payments: 0.00
GSK balance_sheet (annual, 2023-12-31) — Construction In Progress: 2120000000.00
GSK income_statement (annual, 2023-12-31) — Cost Of Revenue: 8565000000.00
GSK balance_sheet (annual, 2023-12-31) — Current Assets: 18644000000.00
GSK balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 156000000.00
GSK balance_sheet (annual, 2023-12-31) — Current Debt: 2657000000.00
GSK balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 2813000000.00
GSK balance_sheet (annual, 2023-12-31) — Current Liabilities: 21068000000.00
GSK balance_sheet (annual, 2023-12-31) — Current Provisions: 744000000.00
GSK cash_flow (annual, 2023-12-31) — Deferred Tax: 756000000.00
GSK balance_sheet (annual, 2023-12-31) — Defined Pension Benefit: 634000000.00
GSK cash_flow (annual, 2023-12-31) — Depreciation: 1082000000.00
GSK cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 2294000000.00
GSK income_statement (annual, 2023-12-31) — Diluted Average Shares: 2055500000.00
GSK income_statement (annual, 2023-12-31) — Diluted EPS: 2.40
GSK income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: 4928000000.00
GSK cash_flow (annual, 2023-12-31) — Dividends Received Cfi: 231000000.00
GSK income_statement (annual, 2023-12-31) — EBIT: 6789000000.00
GSK income_statement (annual, 2023-12-31) — EBITDA: 9083000000.00
GSK cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: -99000000.00
GSK cash_flow (annual, 2023-12-31) — End Cash Position: 2858000000.00
GSK balance_sheet (annual, 2023-12-31) — Financial Assets: 0.00
GSK balance_sheet (annual, 2023-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 224000000.00
GSK cash_flow (annual, 2023-12-31) — Financing Cash Flow: -5641000000.00
GSK balance_sheet (annual, 2023-12-31) — Finished Goods: 1455000000.00
GSK cash_flow (annual, 2023-12-31) — Free Cash Flow: 4424000000.00
GSK cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of Business: -1000000.00
GSK cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of PPE: -12000000.00
GSK income_statement (annual, 2023-12-31) — General And Administrative Expense: 9385000000.00
GSK balance_sheet (annual, 2023-12-31) — Goodwill: 6811000000.00
GSK balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 21579000000.00
GSK balance_sheet (annual, 2023-12-31) — Gross Accounts Receivable: 5990000000.00
GSK balance_sheet (annual, 2023-12-31) — Gross PPE: 20216000000.00
GSK income_statement (annual, 2023-12-31) — Gross Profit: 21763000000.00
GSK balance_sheet (annual, 2023-12-31) — Hedging Assets Current: 130000000.00
GSK income_statement (annual, 2023-12-31) — Interest Expense: 725000000.00
GSK income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 725000000.00
GSK income_statement (annual, 2023-12-31) — Interest Income: 48000000.00
GSK income_statement (annual, 2023-12-31) — Interest Income Non Operating: 48000000.00
GSK cash_flow (annual, 2023-12-31) — Interest Paid Cff: -766000000.00
GSK cash_flow (annual, 2023-12-31) — Interest Received Cfi: 115000000.00
GSK balance_sheet (annual, 2023-12-31) — Inventory: 5498000000.00
GSK balance_sheet (annual, 2023-12-31) — Invested Capital: 30158000000.00
GSK cash_flow (annual, 2023-12-31) — Investing Cash Flow: -1595000000.00
GSK balance_sheet (annual, 2023-12-31) — Investmentin Financial Assets: 1164000000.00
GSK balance_sheet (annual, 2023-12-31) — Investmentsin Associatesat Cost: 55000000.00
GSK balance_sheet (annual, 2023-12-31) — Investmentsin Joint Venturesat Cost: 0.00
GSK cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 10000000.00
GSK cash_flow (annual, 2023-12-31) — Issuance Of Debt: 223000000.00
GSK balance_sheet (annual, 2023-12-31) — Land And Improvements: 6455000000.00
GSK balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 1051000000.00
GSK balance_sheet (annual, 2023-12-31) — Long Term Debt: 14154000000.00
GSK balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 15205000000.00
GSK cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 223000000.00
GSK cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -2260000000.00
GSK balance_sheet (annual, 2023-12-31) — Long Term Equity Investment: 55000000.00
GSK balance_sheet (annual, 2023-12-31) — Long Term Provisions: 495000000.00
GSK balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 10886000000.00
GSK balance_sheet (annual, 2023-12-31) — Minority Interest: -552000000.00
GSK income_statement (annual, 2023-12-31) — Minority Interests: -380000000.00
GSK cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 291000000.00
GSK cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 10000000.00
GSK balance_sheet (annual, 2023-12-31) — Net Debt: 14065000000.00
GSK income_statement (annual, 2023-12-31) — Net Income: 4928000000.00
GSK income_statement (annual, 2023-12-31) — Net Income Common Stockholders: 4928000000.00
GSK income_statement (annual, 2023-12-31) — Net Income Continuous Operations: 5308000000.00
GSK income_statement (annual, 2023-12-31) — Net Income Discontinuous Operations: 0.00
GSK income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: 4928000000.00
GSK income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: 4928000000.00
GSK cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: 5308000000.00
GSK income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: 5308000000.00
GSK cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: -1018000000.00
GSK income_statement (annual, 2023-12-31) — Net Interest Income: -735000000.00
GSK cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 72000000.00
GSK cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -2370000000.00
GSK cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -2037000000.00
GSK income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -735000000.00
GSK cash_flow (annual, 2023-12-31) — Net Other Financing Charges: 341000000.00
GSK balance_sheet (annual, 2023-12-31) — Net PPE: 9957000000.00
GSK cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -1286000000.00
GSK cash_flow (annual, 2023-12-31) — Net Short Term Debt Issuance: -333000000.00
GSK balance_sheet (annual, 2023-12-31) — Net Tangible Assets: -8232000000.00
GSK balance_sheet (annual, 2023-12-31) — Non Current Accrued Expenses: 4000000.00
GSK balance_sheet (annual, 2023-12-31) — Non Current Deferred Revenue: 254000000.00
GSK balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Assets: 6049000000.00
GSK balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 311000000.00
GSK balance_sheet (annual, 2023-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 2340000000.00
GSK income_statement (annual, 2023-12-31) — Normalized EBITDA: 9624000000.00
GSK income_statement (annual, 2023-12-31) — Normalized Income: 5401375000.00
GSK cash_flow (annual, 2023-12-31) — Operating Cash Flow: 6768000000.00
GSK income_statement (annual, 2023-12-31) — Operating Income: 7345000000.00
GSK income_statement (annual, 2023-12-31) — Operating Revenue: 30328000000.00
GSK balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 4056260617.00
GSK balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 1053000000.00
GSK balance_sheet (annual, 2023-12-31) — Other Equity Interest: -288000000.00
GSK balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 14768000000.00
GSK cash_flow (annual, 2023-12-31) — Other Non Cash Items: 470000000.00
GSK balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 5609000000.00
GSK balance_sheet (annual, 2023-12-31) — Other Payable: 346000000.00
GSK balance_sheet (annual, 2023-12-31) — Other Properties: 4000000.00
GSK balance_sheet (annual, 2023-12-31) — Other Receivables: 560000000.00
GSK balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 2246000000.00
GSK income_statement (annual, 2023-12-31) — Other Special Charges: -87000000.00
GSK income_statement (annual, 2023-12-31) — Otherunder Preferred Stock Dividend: 0.00
GSK balance_sheet (annual, 2023-12-31) — Payables: 4563000000.00
GSK balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 126000000.00
GSK balance_sheet (annual, 2023-12-31) — Prepaid Assets: 355000000.00
GSK income_statement (annual, 2023-12-31) — Pretax Income: 6064000000.00
GSK balance_sheet (annual, 2023-12-31) — Properties: 0.00
GSK cash_flow (annual, 2023-12-31) — Purchase Of Business: -1591000000.00
GSK cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: -1030000000.00
GSK cash_flow (annual, 2023-12-31) — Purchase Of PPE: -1314000000.00
GSK balance_sheet (annual, 2023-12-31) — Raw Materials: 1594000000.00
GSK income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 8565000000.00
GSK income_statement (annual, 2023-12-31) — Reconciled Depreciation: 2294000000.00
GSK income_statement (annual, 2023-12-31) — Rent Expense Supplemental: 27000000.00
GSK cash_flow (annual, 2023-12-31) — Repayment Of Debt: -2593000000.00
GSK cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: 0.00
GSK income_statement (annual, 2023-12-31) — Research And Development: 6223000000.00
GSK balance_sheet (annual, 2023-12-31) — Restricted Cash: 190000000.00
GSK income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: 791000000.00
GSK balance_sheet (annual, 2023-12-31) — Retained Earnings: 7239000000.00
GSK cash_flow (annual, 2023-12-31) — Sale Of Business: 1882000000.00
GSK cash_flow (annual, 2023-12-31) — Sale Of Intangibles: 12000000.00
GSK cash_flow (annual, 2023-12-31) — Sale Of Investment: 72000000.00
GSK cash_flow (annual, 2023-12-31) — Sale Of PPE: 28000000.00
GSK income_statement (annual, 2023-12-31) — Selling General And Administration: 9385000000.00
GSK balance_sheet (annual, 2023-12-31) — Share Issued: 4312145983.00
GSK cash_flow (annual, 2023-12-31) — Short Term Debt Issuance: 0.00
GSK cash_flow (annual, 2023-12-31) — Short Term Debt Payments: -333000000.00
GSK income_statement (annual, 2023-12-31) — Special Income Charges: -704000000.00
GSK cash_flow (annual, 2023-12-31) — Stock Based Compensation: 307000000.00
GSK balance_sheet (annual, 2023-12-31) — Stockholders Equity: 13347000000.00
GSK balance_sheet (annual, 2023-12-31) — Tangible Book Value: -8232000000.00
GSK income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -67625000.00
GSK income_statement (annual, 2023-12-31) — Tax Provision: 756000000.00
GSK income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.13
GSK balance_sheet (annual, 2023-12-31) — Taxes Receivable: 938000000.00
GSK cash_flow (annual, 2023-12-31) — Taxes Refund Paid: -1328000000.00
GSK balance_sheet (annual, 2023-12-31) — Total Assets: 59005000000.00
GSK balance_sheet (annual, 2023-12-31) — Total Capitalization: 27501000000.00
GSK balance_sheet (annual, 2023-12-31) — Total Debt: 18018000000.00
GSK balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 12795000000.00
GSK income_statement (annual, 2023-12-31) — Total Expenses: 22983000000.00
GSK balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 46210000000.00
GSK balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 40361000000.00
GSK balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 25142000000.00
GSK income_statement (annual, 2023-12-31) — Total Operating Income As Reported: 6745000000.00
GSK income_statement (annual, 2023-12-31) — Total Other Finance Cost: 58000000.00
GSK balance_sheet (annual, 2023-12-31) — Total Tax Payable: 500000000.00
GSK income_statement (annual, 2023-12-31) — Total Unusual Items: -541000000.00
GSK income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -541000000.00
GSK balance_sheet (annual, 2023-12-31) — Tradeand Other Payables Non Current: 924000000.00
GSK balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 255885366.00
GSK balance_sheet (annual, 2023-12-31) — Work In Process: 2449000000.00
GSK balance_sheet (annual, 2023-12-31) — Working Capital: -2424000000.00
GSK cash_flow (quarterly, 2024-09-30) — Gain Loss On Sale Of Business: 0.00
GSK cash_flow (quarterly, 2024-09-30) — Long Term Debt Payments: 1000000.00
GSK balance_sheet (quarterly, 2024-09-30) — Other Investments: 1023000000.00
GSK balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 1940000000.00
GSK income_statement (quarterly, 2024-09-30) — Other Operating Expenses: 335000000.00
GSK income_statement (quarterly, 2024-09-30) — Special Income Charges: 0.00
GSK income_statement (quarterly, 2024-09-30) — Total Unusual Items: 0.00
GSK income_statement (quarterly, 2024-09-30) — Total Unusual Items Excluding Goodwill: 0.00
GSK income_statement (annual, 2024-12-31) — +Operating Expense: 16786000000.00
GSK income_statement (annual, 2024-12-31) — +Total Revenue: 31376000000.00
GSK balance_sheet (annual, 2024-12-31) — Accounts Payable: 3462000000.00
GSK balance_sheet (annual, 2024-12-31) — Accounts Receivable: 5563000000.00
GSK balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -10483000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -10483000000.00
GSK balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 3473000000.00
GSK balance_sheet (annual, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -99000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -99000000.00
GSK cash_flow (annual, 2024-12-31) — Amortization Cash Flow: 1454000000.00
GSK balance_sheet (annual, 2024-12-31) — Assets Held For Sale Current: 3000000.00
GSK balance_sheet (annual, 2024-12-31) — Available For Sale Securities: 848000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Available For Sale Securities: 848000000.00
GSK income_statement (annual, 2024-12-31) — Basic Average Shares: 2038500000.00
GSK income_statement (annual, 2024-12-31) — Basic EPS: 1.26
GSK cash_flow (annual, 2024-12-31) — Beginning Cash Position: 2858000000.00
GSK balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 636000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Buildings And Improvements: 636000000.00
GSK cash_flow (annual, 2024-12-31) — Capital Expenditure: -2982000000.00
GSK balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 1102000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Capital Lease Obligations: 1102000000.00
GSK balance_sheet (annual, 2024-12-31) — Capital Stock: 1348000000.00
GSK balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 3693000000.00
GSK balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 3714000000.00
GSK cash_flow (annual, 2024-12-31) — Cash Dividends Paid: -2444000000.00
GSK cash_flow (annual, 2024-12-31) — Change In Inventory: -294000000.00
GSK cash_flow (annual, 2024-12-31) — Change In Other Current Assets: 999000000.00
GSK cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: 1834000000.00
GSK cash_flow (annual, 2024-12-31) — Change In Payable: -789000000.00
GSK cash_flow (annual, 2024-12-31) — Change In Receivables: 340000000.00
GSK cash_flow (annual, 2024-12-31) — Change In Working Capital: 2090000000.00
GSK cash_flow (annual, 2024-12-31) — Changes In Cash: 599000000.00
GSK balance_sheet (annual, 2024-12-31) — Common Stock: 1348000000.00
GSK cash_flow (annual, 2024-12-31) — Common Stock Dividend Paid: -2444000000.00
GSK balance_sheet (annual, 2024-12-31) — Common Stock Equity: 13671000000.00
GSK cash_flow (annual, 2024-12-31) — Common Stock Issuance: 20000000.00
GSK cash_flow (annual, 2024-12-31) — Common Stock Payments: 0.00
GSK balance_sheet (annual, 2024-12-31) — Construction In Progress: 2320000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Construction In Progress: 2320000000.00
GSK income_statement (annual, 2024-12-31) — Cost Of Revenue: 9048000000.00
GSK balance_sheet (annual, 2024-12-31) — Current Assets: 16997000000.00
GSK balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 168000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Current Capital Lease Obligation: 168000000.00
GSK balance_sheet (annual, 2024-12-31) — Current Debt: 2181000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Current Debt: 2181000000.00
GSK balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 2349000000.00
GSK balance_sheet (annual, 2024-12-31) — Current Liabilities: 21697000000.00
GSK balance_sheet (annual, 2024-12-31) — Current Provisions: 1946000000.00
GSK cash_flow (annual, 2024-12-31) — Deferred Tax: 526000000.00
GSK balance_sheet (annual, 2024-12-31) — Defined Pension Benefit: 898000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Defined Pension Benefit: 898000000.00
GSK cash_flow (annual, 2024-12-31) — Depreciation: 1097000000.00
GSK cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 2551000000.00
GSK balance_sheet (annual, 2024-12-31) — Derivative Product Liabilities: 0.00
GSK income_statement (annual, 2024-12-31) — Diluted Average Shares: 2071000000.00
GSK income_statement (annual, 2024-12-31) — Diluted EPS: 1.24
GSK income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: 2575000000.00
GSK cash_flow (annual, 2024-12-31) — Dividends Received Cfi: 31000000.00
GSK cash_flow (quarterly, 2024-12-31) — Dividends Received Cfi: 0.00
GSK income_statement (annual, 2024-12-31) — EBIT: 4117000000.00
GSK income_statement (annual, 2024-12-31) — EBITDA: 6668000000.00
GSK cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -54000000.00
GSK cash_flow (annual, 2024-12-31) — End Cash Position: 3403000000.00
GSK balance_sheet (annual, 2024-12-31) — Financial Assets: 1000000.00
GSK balance_sheet (annual, 2024-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 288000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 288000000.00
GSK cash_flow (annual, 2024-12-31) — Financing Cash Flow: -4726000000.00
GSK balance_sheet (annual, 2024-12-31) — Finished Goods: 1625000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Finished Goods: 1625000000.00
GSK cash_flow (annual, 2024-12-31) — Free Cash Flow: 3572000000.00
GSK cash_flow (annual, 2024-12-31) — Gain Loss On Investment Securities: -10000000.00
GSK cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of Business: 5000000.00
GSK cash_flow (quarterly, 2024-12-31) — Gain Loss On Sale Of Business: 5000000.00
GSK cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of PPE: -170000000.00
GSK income_statement (annual, 2024-12-31) — General And Administrative Expense: 11015000000.00
GSK balance_sheet (annual, 2024-12-31) — Goodwill: 6982000000.00
GSK balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 22497000000.00
GSK balance_sheet (annual, 2024-12-31) — Gross Accounts Receivable: 5563000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Gross Accounts Receivable: 5563000000.00
GSK balance_sheet (annual, 2024-12-31) — Gross PPE: 20556000000.00
GSK income_statement (annual, 2024-12-31) — Gross Profit: 22328000000.00
GSK balance_sheet (annual, 2024-12-31) — Hedging Assets Current: 109000000.00
GSK income_statement (annual, 2024-12-31) — Interest Expense: 640000000.00
GSK income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 640000000.00
GSK income_statement (annual, 2024-12-31) — Interest Income: 60000000.00
GSK income_statement (annual, 2024-12-31) — Interest Income Non Operating: 60000000.00
GSK cash_flow (annual, 2024-12-31) — Interest Paid Cff: -632000000.00
GSK cash_flow (annual, 2024-12-31) — Interest Received Cfi: 138000000.00
GSK balance_sheet (annual, 2024-12-31) — Inventory: 5669000000.00
GSK balance_sheet (annual, 2024-12-31) — Invested Capital: 29555000000.00
GSK cash_flow (annual, 2024-12-31) — Investing Cash Flow: -1229000000.00
GSK balance_sheet (annual, 2024-12-31) — Investmentin Financial Assets: 1136000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Investmentin Financial Assets: 1136000000.00
GSK balance_sheet (annual, 2024-12-31) — Investmentsin Associatesat Cost: 96000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Investmentsin Associatesat Cost: 96000000.00
GSK balance_sheet (annual, 2024-12-31) — Investmentsin Joint Venturesat Cost: 0.00
GSK balance_sheet (quarterly, 2024-12-31) — Investmentsin Joint Venturesat Cost: 0.00
GSK cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 20000000.00
GSK cash_flow (annual, 2024-12-31) — Issuance Of Debt: 1341000000.00
GSK balance_sheet (annual, 2024-12-31) — Land And Improvements: 6375000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Land And Improvements: 6375000000.00
GSK balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 934000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Long Term Capital Lease Obligation: 934000000.00
GSK balance_sheet (annual, 2024-12-31) — Long Term Debt: 13703000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Long Term Debt: 13703000000.00
GSK balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 14637000000.00
GSK cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 1075000000.00
GSK cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -1615000000.00
GSK cash_flow (quarterly, 2024-12-31) — Long Term Debt Payments: -1615000000.00
GSK balance_sheet (annual, 2024-12-31) — Long Term Equity Investment: 96000000.00
GSK balance_sheet (annual, 2024-12-31) — Long Term Provisions: 589000000.00
GSK balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 11217000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 11217000000.00
GSK balance_sheet (annual, 2024-12-31) — Minority Interest: -585000000.00
GSK income_statement (annual, 2024-12-31) — Minority Interests: -376000000.00
GSK cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 1368000000.00
GSK cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 20000000.00
GSK balance_sheet (annual, 2024-12-31) — Net Debt: 12191000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Net Debt: 12191000000.00
GSK income_statement (annual, 2024-12-31) — Net Income: 2575000000.00
GSK income_statement (annual, 2024-12-31) — Net Income Common Stockholders: 2575000000.00
GSK income_statement (annual, 2024-12-31) — Net Income Continuous Operations: 2951000000.00
GSK income_statement (annual, 2024-12-31) — Net Income Discontinuous Operations: 0.00
GSK income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 2575000000.00
GSK income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 2575000000.00
GSK cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: 2951000000.00
GSK income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: 2951000000.00
GSK cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -1452000000.00
GSK income_statement (annual, 2024-12-31) — Net Interest Income: -603000000.00
GSK cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 21000000.00
GSK cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -1166000000.00
GSK cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -540000000.00
GSK income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -603000000.00
GSK cash_flow (annual, 2024-12-31) — Net Other Financing Charges: 138000000.00
GSK cash_flow (annual, 2024-12-31) — Net Other Investing Changes: -1000000.00
GSK balance_sheet (annual, 2024-12-31) — Net PPE: 10073000000.00
GSK cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -1334000000.00
GSK cash_flow (annual, 2024-12-31) — Net Short Term Debt Issuance: -626000000.00
GSK balance_sheet (annual, 2024-12-31) — Net Tangible Assets: -8826000000.00
GSK balance_sheet (annual, 2024-12-31) — Non Current Accrued Expenses: 6000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Non Current Accrued Expenses: 6000000.00
GSK balance_sheet (annual, 2024-12-31) — Non Current Deferred Revenue: 165000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Non Current Deferred Revenue: 165000000.00
GSK balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 6757000000.00
GSK balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 382000000.00
GSK balance_sheet (annual, 2024-12-31) — Non Current Pension And Other Postretirement Benefit Plans: 1864000000.00
GSK income_statement (annual, 2024-12-31) — Normalized EBITDA: 8127000000.00
GSK income_statement (annual, 2024-12-31) — Normalized Income: 3813282714.98
GSK cash_flow (annual, 2024-12-31) — Operating Cash Flow: 6554000000.00
GSK income_statement (annual, 2024-12-31) — Operating Income: 5542000000.00
GSK income_statement (annual, 2024-12-31) — Operating Revenue: 31376000000.00
GSK balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 4080818273.00
GSK balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 1172000000.00
GSK balance_sheet (annual, 2024-12-31) — Other Equity Interest: -397000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Other Equity Interest: -397000000.00
GSK balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 15515000000.00
GSK cash_flow (annual, 2024-12-31) — Other Non Cash Items: 398000000.00
GSK balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 6108000000.00
GSK income_statement (annual, 2024-12-31) — Other Operating Expenses: 9000000.00
GSK income_statement (quarterly, 2024-12-31) — Other Operating Expenses: -1177000000.00
GSK balance_sheet (annual, 2024-12-31) — Other Payable: 420000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Other Payable: 420000000.00
GSK balance_sheet (annual, 2024-12-31) — Other Properties: 8000000.00
GSK balance_sheet (annual, 2024-12-31) — Other Receivables: 436000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Other Receivables: 436000000.00
GSK balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 21000000.00
GSK income_statement (annual, 2024-12-31) — Other Special Charges: -518000000.00
GSK income_statement (annual, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
GSK balance_sheet (annual, 2024-12-31) — Payables: 4585000000.00
GSK balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 125000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 125000000.00
GSK balance_sheet (annual, 2024-12-31) — Prepaid Assets: 390000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 390000000.00
GSK income_statement (annual, 2024-12-31) — Pretax Income: 3477000000.00
GSK balance_sheet (annual, 2024-12-31) — Properties: 0.00
GSK balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
GSK cash_flow (annual, 2024-12-31) — Purchase Of Business: -988000000.00
GSK cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -1583000000.00
GSK cash_flow (annual, 2024-12-31) — Purchase Of PPE: -1399000000.00
GSK balance_sheet (annual, 2024-12-31) — Raw Materials: 1361000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Raw Materials: 1361000000.00
GSK income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 9048000000.00
GSK income_statement (annual, 2024-12-31) — Reconciled Depreciation: 2551000000.00
GSK income_statement (annual, 2024-12-31) — Rent Expense Supplemental: 30000000.00
GSK cash_flow (annual, 2024-12-31) — Repayment Of Debt: -2507000000.00
GSK cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: 0.00
GSK income_statement (annual, 2024-12-31) — Research And Development: 6401000000.00
GSK balance_sheet (annual, 2024-12-31) — Restricted Cash: 177000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Restricted Cash: 177000000.00
GSK income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 1751000000.00
GSK balance_sheet (annual, 2024-12-31) — Retained Earnings: 7796000000.00
GSK cash_flow (annual, 2024-12-31) — Sale Of Business: 2356000000.00
GSK cash_flow (annual, 2024-12-31) — Sale Of Intangibles: 131000000.00
GSK cash_flow (annual, 2024-12-31) — Sale Of Investment: 21000000.00
GSK cash_flow (annual, 2024-12-31) — Sale Of PPE: 65000000.00
GSK income_statement (annual, 2024-12-31) — Selling General And Administration: 11015000000.00
GSK balance_sheet (annual, 2024-12-31) — Share Issued: 4314303734.00
GSK cash_flow (annual, 2024-12-31) — Short Term Debt Issuance: 266000000.00
GSK cash_flow (annual, 2024-12-31) — Short Term Debt Payments: -892000000.00
GSK income_statement (annual, 2024-12-31) — Special Income Charges: -1233000000.00
GSK income_statement (quarterly, 2024-12-31) — Special Income Charges: -1233000000.00
GSK cash_flow (annual, 2024-12-31) — Stock Based Compensation: 344000000.00
GSK balance_sheet (annual, 2024-12-31) — Stockholders Equity: 13671000000.00
GSK balance_sheet (annual, 2024-12-31) — Tangible Book Value: -8826000000.00
GSK income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -220717285.02
GSK income_statement (annual, 2024-12-31) — Tax Provision: 526000000.00
GSK income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.15
GSK balance_sheet (annual, 2024-12-31) — Taxes Receivable: 936000000.00
GSK cash_flow (annual, 2024-12-31) — Taxes Refund Paid: -1307000000.00
GSK balance_sheet (annual, 2024-12-31) — Total Assets: 59463000000.00
GSK balance_sheet (annual, 2024-12-31) — Total Capitalization: 27374000000.00
GSK balance_sheet (annual, 2024-12-31) — Total Debt: 16986000000.00
GSK balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 13086000000.00
GSK income_statement (annual, 2024-12-31) — Total Expenses: 25834000000.00
GSK balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 46377000000.00
GSK balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 42466000000.00
GSK balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 24680000000.00
GSK income_statement (annual, 2024-12-31) — Total Operating Income As Reported: 4021000000.00
GSK income_statement (annual, 2024-12-31) — Total Other Finance Cost: 23000000.00
GSK balance_sheet (annual, 2024-12-31) — Total Tax Payable: 703000000.00
GSK income_statement (annual, 2024-12-31) — Total Unusual Items: -1459000000.00
GSK income_statement (quarterly, 2024-12-31) — Total Unusual Items: -1459000000.00
GSK income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -1459000000.00
GSK income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: -1459000000.00
GSK balance_sheet (annual, 2024-12-31) — Tradeand Other Payables Non Current: 929000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Tradeand Other Payables Non Current: 929000000.00
GSK balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 233485461.00
GSK balance_sheet (annual, 2024-12-31) — Work In Process: 2683000000.00
GSK balance_sheet (quarterly, 2024-12-31) — Work In Process: 2683000000.00
GSK balance_sheet (annual, 2024-12-31) — Working Capital: -4700000000.00
GSK income_statement (quarterly, 2025-03-31) — +Operating Expense: 3363000000.00
GSK income_statement (quarterly, 2025-03-31) — +Total Revenue: 7516000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 15149000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 7059000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 3484000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Assets Held For Sale Current: 4000000.00
GSK income_statement (quarterly, 2025-03-31) — Basic Average Shares: 2044000000.00
GSK income_statement (quarterly, 2025-03-31) — Basic EPS: 0.79
GSK cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 3403000000.00
GSK cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -448000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Capital Stock: 1349000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 4464000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 4485000000.00
GSK cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: -612000000.00
GSK cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -788000000.00
GSK cash_flow (quarterly, 2025-03-31) — Changes In Cash: 859000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Common Stock: 1349000000.00
GSK cash_flow (quarterly, 2025-03-31) — Common Stock Dividend Paid: -612000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 14157000000.00
GSK cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 12000000.00
GSK cash_flow (quarterly, 2025-03-31) — Common Stock Payments: -247000000.00
GSK income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 1937000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Current Assets: 18085000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 1958000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 20831000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Current Provisions: 1840000000.00
GSK cash_flow (quarterly, 2025-03-31) — Deferred Tax: 336000000.00
GSK cash_flow (quarterly, 2025-03-31) — Depreciation: 823000000.00
GSK cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 823000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Derivative Product Liabilities: 2000000.00
GSK income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 2068500000.00
GSK income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.79
GSK income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 1624000000.00
GSK cash_flow (quarterly, 2025-03-31) — Dividends Received Cfi: 0.00
GSK income_statement (quarterly, 2025-03-31) — EBIT: 2270000000.00
GSK income_statement (quarterly, 2025-03-31) — EBITDA: 3093000000.00
GSK cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: -11000000.00
GSK cash_flow (quarterly, 2025-03-31) — End Cash Position: 4251000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Financial Assets: 0.00
GSK cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 858000000.00
GSK cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 697000000.00
GSK income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 2070000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Goodwill: 6926000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 23184000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Gross PPE: 9971000000.00
GSK income_statement (quarterly, 2025-03-31) — Gross Profit: 5579000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 95000000.00
GSK income_statement (quarterly, 2025-03-31) — Interest Expense: 162000000.00
GSK income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 162000000.00
GSK income_statement (quarterly, 2025-03-31) — Interest Income: 54000000.00
GSK income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 54000000.00
GSK cash_flow (quarterly, 2025-03-31) — Interest Paid Cff: -69000000.00
GSK cash_flow (quarterly, 2025-03-31) — Interest Received Cfi: 53000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Inventory: 6000000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Invested Capital: 14157000000.00
GSK cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -1144000000.00
GSK cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 12000000.00
GSK cash_flow (quarterly, 2025-03-31) — Issuance Of Debt: 2077000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 16474000000.00
GSK cash_flow (quarterly, 2025-03-31) — Long Term Debt Issuance: 2018000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 99000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 555000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Minority Interest: -503000000.00
GSK income_statement (quarterly, 2025-03-31) — Minority Interests: -148000000.00
GSK cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: -826000000.00
GSK cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: -235000000.00
GSK income_statement (quarterly, 2025-03-31) — Net Income: 1624000000.00
GSK income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 1624000000.00
GSK income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 1772000000.00
GSK income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1624000000.00
GSK income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1624000000.00
GSK cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 1772000000.00
GSK income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 1772000000.00
GSK cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: -164000000.00
GSK income_statement (quarterly, 2025-03-31) — Net Interest Income: -108000000.00
GSK cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 0.00
GSK cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: 1918000000.00
GSK cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: 2018000000.00
GSK income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -108000000.00
GSK cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -29000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Net PPE: 9971000000.00
GSK cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -207000000.00
GSK cash_flow (quarterly, 2025-03-31) — Net Short Term Debt Issuance: -100000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: -9027000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 6410000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 404000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 1870000000.00
GSK income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 3093000000.00
GSK income_statement (quarterly, 2025-03-31) — Normalized Income: 1624000000.00
GSK cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 1145000000.00
GSK income_statement (quarterly, 2025-03-31) — Operating Income: 2216000000.00
GSK income_statement (quarterly, 2025-03-31) — Operating Revenue: 7516000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 4084314542.00
GSK balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 1175000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 16258000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Other Investments: 933000000.00
GSK cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 108000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 2023000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 6884000000.00
GSK income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 11000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Other Properties: 9971000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 21000000.00
GSK income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
GSK balance_sheet (quarterly, 2025-03-31) — Payables: 15777000000.00
GSK income_statement (quarterly, 2025-03-31) — Pretax Income: 2108000000.00
GSK cash_flow (quarterly, 2025-03-31) — Purchase Of Business: -826000000.00
GSK cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: -240000000.00
GSK cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -208000000.00
GSK income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 1937000000.00
GSK income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 823000000.00
GSK cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -159000000.00
GSK cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: -247000000.00
GSK income_statement (quarterly, 2025-03-31) — Research And Development: 1462000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 8307000000.00
GSK cash_flow (quarterly, 2025-03-31) — Sale Of Business: 0.00
GSK cash_flow (quarterly, 2025-03-31) — Sale Of Intangibles: 76000000.00
GSK cash_flow (quarterly, 2025-03-31) — Sale Of PPE: 1000000.00
GSK income_statement (quarterly, 2025-03-31) — Selling General And Administration: 2070000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Share Issued: 4315221732.00
GSK cash_flow (quarterly, 2025-03-31) — Short Term Debt Issuance: 59000000.00
GSK cash_flow (quarterly, 2025-03-31) — Short Term Debt Payments: -159000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 14157000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: -9027000000.00
GSK income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
GSK income_statement (quarterly, 2025-03-31) — Tax Provision: 336000000.00
GSK income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.16
GSK balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 442000000.00
GSK cash_flow (quarterly, 2025-03-31) — Taxes Refund Paid: -156000000.00
GSK balance_sheet (quarterly, 2025-03-31) — Total Assets: 60705000000.00